Together these data suggest that inhibition of the P2X7 receptor to attenuate NLRP3 inflammasome activation may be a potential therapeutic approach for the treatment of fibromyalgia (D'Amico et al. 2021). Here, NLRP3 is linked to fibromyalgia.